Company intelligence / Profile preview

SmartCatch

Ownership: Private
Development stage: Other

Overview

SmartCatch has developed a proprietary microfiltration-based liquid biopsy platform enabling the direct isolation and multiomic analysis of circulating tumor cells from whole blood. The technology aims to improve cancer diagnosis, monitoring, and personalization of therapy by providing minimally invasive access to real-time tumor heterogeneity data. The company’s products are designed for routine clinical use and research applications in oncology. Commercial launch of their laboratory equipment was anticipated as of the latest updates.

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic tool
Industry: Molecular Diagnostics

Partnerships

LAAS-CNRSCHU de Rangueil urology department

Beyond the preview

Go deeper on SmartCatch.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SmartCatch.

Explore the full profile